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Abstract : Background : In clinical practice, a large proportion of patients with multiple congenital anomalies 
and/or intellectual disabilities (MCA / ID) lacks a specific diagnosis. Recently, next-generation sequencing (NGS) 
has become an efficient strategy for genetic diagnosis of patients with MCA/ID. Objective : To review the utility 
of NGS for the diagnosis of patients with MCA / ID. Method : Patients with MCA/ID were recruited between 2013 
and 2017. Molecular diagnosis was performed using NGS-based targeted panel sequencing for 4,813 genes. Prom-
ising causative variants underwent confirmation by Sanger sequencing or chromosomal microarray. Results : 
Eighteen patients with MCA/ID were enrolled in this study. Of them, 8 cases (44%) were diagnosed by targeted 
panel sequencing. Most of diagnosed patients were able to receive better counseling and more appropriate medi-
cal management. Conclusion : NGS-based targeted panel sequencing seems to be an effective testing strategy for 
diagnosis of patients with MCA/ID. J. Med. Invest. 67 : 246-249, August, 2020
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INTRODUCTION
 
In neonatal intensive care units (NICUs) and pediatric out-
patient clinics, patients with multiple congenital anomalies and/
or intellectual disabilities (MCA/ID) of unknown etiology are 
common. The ability to provide optimal clinical management is 
dependent on identification of the underlying genetic cause of the 
disease (1). The strategy for selecting genomic diagnostic tests 
is highly dependent on the presenting clinical phenotype and 
differential diagnoses (2). Next-generation sequencing (NGS), 
particularly whole-exome sequencing (WES) and targeted-panel 
sequencing (TPS), have been adopted in clinical investigations 
for patients with undiagnosed MCA/ID (1,3). This is because 
sequencing costs have become more reasonable, and informat-
ics approaches to NGS reporting have been developed (4). This 
study reviewed the utility of TPS for molecular diagnosis of pa-
tients with MCA/ID of unknown etiology in our hospital. 
METHODS
This study was approved by the ethics committee at Tokushima 
University and all parents provided written informed consent 
prior to enrolment. Patients with MCA/ID were recruited for 
this pilot study between 2013 and 2017 from the NICU or pedi-
atric outpatient clinic. 
We extracted genomic DNA from lymphocytes according to 
standard methods. TPS was performed using the TruSight One 
Sequencing Panel kit (Illumina, San Diego, CA, USA), which 
includes 4813 genes from the Human Gene Mutation Database 
(www.hgmd.cf.ac.uk/ac/index.php) and the Online Mendelian 
Inheritance in Man database (www.genetests.org), along with 
other genes identified from commercially available panels, and 
a MiSeq benchtop sequencer (Illumina), followed by our pipe-
line for NGS data analysis with a software update specific for 
a bioinformatics pipeline (5). To identify presumably pathogenic 
single-nucleotide variants, we excluded sequence variants with 
low-allele frequencies, that is, > 0.01 included in the 1000 Ge-
nomes Project database (http://www.1000genomes.org), National 
Heart, Lung, and Blood Institute Grand Opportunity Exome 
Sequencing Project (http://evs.gs.washington.edu/EVS), Human 
Genetic Variation Database (http://www.genome.med.kyoto-u.
ac.jp/SnpDB) and integrative Japanese Genome Variation Da-
tabase (https://ijgvd.megabank.tohoku.ac.jp), and compared 
candidate variants with the Human Gene Mutation Database 
Professional (http://www.hgmd.org/) and ClinVar (http://www.
ncbi.nlm.nih.gov/clinvar/). Detection of copy number variants 
using TPS data with a resolution of a single exon to several 
exons, depending on exon size, was performed as described 
previously (5). Validation of single nucleotide variants or small 
insertions and deletions were performed by Sanger sequencing. 
Validation and fine mapping of gross deletions were performed 
by chromosomal microarray using an Affymetrix CytoScan HD 
chromosome microarray platform (Affymetrix, Santa Clara, CA, 
USA).
RESULTS
Eighteen patients with MCA/ID were enrolled in the present 
study. Six patients were enrolled during hospitalization in the 
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NICU, whereas 12 patients were enrolled from pediatric outpa-
tient clinic (Table 1). TPS revealed a molecular diagnosis for 8 
of 18 (44%) patients (6-10) (Table 2). Clinical benefits from the 
results of TPS are also shown in Table 2. Case 2 was clinically 
undiagnosed, but molecularly diagnosed with Lowe syndrome 
by detecting 1.7 Mb deletion including OCRL1 at 6 months of age, 
and this early diagnosis by TPS could lead to better counseling 
and early initiation of treatment for rickets and renal disorder 
involving the proximal renal tubules (7). Case 4 presented with 
cardiac tumors detected on fetal ultrasonography, with tuber-
ous sclerosis suspected from clinical evaluation (Table 1). TPS 
revealed a 47.8 Kb deletion involving a part of PKD1 and a part 
of TSC2. This early diagnosis made it possible not only to initiate 
anti-epileptic pharmacotherapy, but also to detect polycystic kid-
ney disease at preclinical stage. In Case 5, the early diagnosis of 
achondroplasia allowed us to enact precautions against sudden 
death due to obstructive respiratory arrest. The established di-
agnosis by TPS provided beneficial information to care providers 
regarding the natural history and allowed accurate counseling 
about reproductive risk. In Case 1 with CHARGE syndrome 
diagnosed by detecting frameshift deletion in CHD7, however, ge-
netic counseling was provided at 147 days of age, but his mother 
Table 1.　Clinical features and tentative diagnosis before genetic testing.
Case Tentative clinical diagnosis Sex Enrollment Clinical description
1*(6) CHARGE syndrome M NICU, 3m
cleft lip and palate,choanal stenosis, incomplete 
atrioventricular septal defect, aortic valve stenosis, 
dysphagia, growth retardation, cryptorchidism, 
micropenis, auricular malformation, deafness
2*(7) Lowe syndrome M Outpatient, 6m
cataract, growth retardation, right cryptorchidism, 
inguinal hernia, hypotonia, nystagmus, delayed 
development, mild ventriculomegaly, short stature, 
renal tubular dysfunction
3 Developmental delay F Outpatient, 6m
mild developmental delay, imperforate anus, supura-
valvular aortic stenosis, peripheral pulmonary artery 
stenosis
4 Tuberous sclerosis M NICU, 1m
cardiac rhabdomyomas, epilepsy, polycystic
kidney, subepedymal giant cell astrocytoma, retinal 
hamartoma
5 Achondroplasia M NICU, 2m macrocephaly, short arms and legs, frontal bossing, mid face hypoplasia
6*(8) MCA M Outpatient, 4m patent ductus arteriosus, ventricular septal defect, dilated cardiomyopathy, malrotation of intestine
7*(9) MCA/ID M Outpatient, 4y patent ductus arteriosus, forehead protrusions, flat nose bridge, West syndrome, severe ID
8*(10) Rett syndrome M Outpatient, 3y
hand-wringing, ID, declaration of head growth, loss 
of acquired hand skill, loss of acquired language 
skill, impaired gait ability, breathing disturbances, 
inappropriate laughing/screaming spells
9 Townes Brocks syndrome F NICU, 9m
Tetralogy of Fallot, anal atresia, micrognathia, right 
anotia, left microtia, hypoplasia of the right thumb, 
hearing loss, vertebral anomalies, right ectopic 
kidney, epilepsy
10 Rubinstein-Taybi syndrome M Outpatient, 5y myopathy, mental retardation, epilepsy
11 Galloway Mowat syndrome M NICU, 4m congenital nephrotic syndrome, intractable epilepsy, progressive brain atrophy, pulmonary stenosis
12 ID F Outpatient, 3y severe fetal growth restriction, developmental delay, scoliosis, extremely low birth weight infant
13 Blepharophimosis ptosisepicanthus inversus syndrome F Outpatient , 5m blepharophimosis, ptosis, epicanthus inversus
14 MCA/ID F Outpatient , 11y hypertelorism, upslanted palpebral fissure, prominent nasal bridge, mental retardation
15 MCA/ID M Outpatient, 9y hypertelorism, mental retardation, autism spectrum disorder, low set ears
16 MCA/ID M Outpatient, 4y
hypertelorism, short columella, frontal bossing, 
mental retardation, breath-holoding spells, low set 
ears, craniosynostosis
17 MCA/ID F Outpatient , 13y
frontal bossing, mental retardation, migrating partial 
seizures of infancy, thick lip vermilion, tall chin, 
repeated hand-rubbing
18 MCA/ID F Outpatient, 11y
Severe ID, micrognathia, frontal bossing, auricular 
deformities, anal atresia, non-compaction of left 
ventricle, laryngomalacia
* Numbers indicate reference numbers.
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did not accept his diagnosis (6). His parents therefore did not 




Conventional Sanger sequencing has routinely been used to 
identify pathogenic variants for genetic diseases, but is labori-
ous, expensive and time-consuming for large genes with numer-
ous exons, such as CHD7 (37 exons covering 8,994 bp of coding 
sequence), as well as for multiple candidate genes (6, 11) TPS 
has recently been used for candidate or known disease-associ-
ated genes to diagnose patients with various types of disorders 
including MCA/ID (12). Technological advances have led to the 
ability to sequence and interpret the entire genome in less than 
2 weeks (7). 
According to previous reports, NGS revealed the causative 
gene in 40-59% of patients with MCA in NICU (2). The present 
study showed a similar frequency of diagnosis (44%) in MCA/
ID. Because Case 1 did not present with coloboma, which is 
seen in 80-90% cases of CHARGE syndrome, it was difficult to 
obtain the definitive diagnosis due to the wide variance in the 
phenotype without objective evidence provided by TPS. By TPS, 
several syndromes were diagnosed before obtaining distinctive 
features of the face. Case 3 was diagnosed with Williams-Beuren 
syndrome at 6 months old and Case 6 was diagnosed with 1p36 
deletion syndrome at 4 months of age (8). If we waited until the 
typical clinical features appeared in both cases, we could reach 
a diagnosis with fluorescence in situ hybridization for the specific 
chromosomal regions once the candidate diseases came to mind 
due to distinctive clinical features of the face. Because the early 
diagnosis allows the possibility of better counseling based on 
accurate outcomes and some degree of relief for family anxiety, 
early application of TPS may be suitable for analyses of patients 
with uncertain clinical phenotypes including MCA/ID. 
An evaluation of the “best time” to pursue NGS is necessary, 
to clarify whether this method should be used as the first ap-
proach in the NICU or as a final investigation in an outpatient 
clinic (2). Some have argued that early testing by NGS will save 
money and time by ending the “diagnostic odyssey” compared 
with multiple serial testing. An expanded sample of patients, 
identified consecutively, and investigated prospectively with 
appropriate controls, will help to answer who and when should 
be offered NGS. 
Several limitations need to be considered for interpreting the 
present results. First, the rate of genetic diagnosis is affected 
by the fact that this study includes patients whose clinical diag-
noses are almost definitive based on clinical symptoms such as 
case 4 and case 5. Second, because we used TPS instead of WES, 
pathogenic variants in the some newly identified disease-causing 
genes may be missed by genetic testing. In addition, it is possible 
that variants within promoter and intronic regions, which would 
affect the transcription and splicing, of disease-causing genes 
may be missed by TPS. Analysis of transcripts by microarray or 
RNA sequencing could reveal the underlying pathogenesis. 
CONCLUSION
TPS was useful for providing established diagnosis in patients 
with MCA/ID, although further large study is required. 
Table 2.　Details of pathogenic variants identified in molecularly diagnosed patients.
Case affected gene mutation type NCBI Ref Seq cDNA and proteinchanges identified
molecular diagnosis
(OMIM no)
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4 TSC2, PKD1 partial deletion NM_000297.4
47.8 Kb deletion




















gross deletion - 2.7Mb deletion at1p36.33-p36.32
1p36 deletion
 syndrome (607872) better counseling Complete








8*(10) MECP2 duplication NM_001110792.1 c.23_27dupp.Ser10Argfs*36
Rett syndrome
(312750) better counseling Complete
* Numbers indicate reference numbers.
NCBI, National Center for Biotechnology Information (US) 
cDNA, complementary DNA
OMIM, Online Mendelian Inheritance in Man.
249The Journal of Medical Investigation   Vol. 67  August  2020
ACKNOWLEDGEMENT
We thank Hideaki Horikawa and Akiko Wabtanabe (Support 
Center for Advanced Medical Sciences, Graduate School of Bio-
medical Sciences, Tokushima University, Tokushima, Japan) for 
technical assistance. 




1.  Brett M, McPherson J, Zang ZJ, Lai A, Tan ES, Ng I, Ong 
LC, Cham B, Tan P, Rozen S, Tan EC : Massively parallel 
sequencing of patients with intellectual disability, congen-
ital anomalies and/or autism spectrum disorders with a 
targeted gene panel. PLoS One 9(4) : 1-9, 2014. doi : 10.1371/
journal.pone.0093409
2.  Bowdin SC : The clinical utility of next-generation sequenc-
ing in the neonatal intensive care unit. Cmaj 188(11) : 786-
787, 2016. doi : 10.1503/cmaj.160490
3.  Abou Tayoun AN, Krock B, Spinner NB : Sequencing-based 
diagnostics for pediatric genetic diseases : progress and po-
tential. Expert Rev Mol Diagn 16(9) : 987-999, 2016. doi : 10
.1080/14737159.2016.1209411
4.  Webber DM, Macleod SL, Bamshad MJ, Shaw GM, Finnell 
RH, Shete SS, Witte JS, Erickson SW,   Murphy LD, Hobbs 
C : Developments in our understanding of the genetic basis 
of birth defects. Birth Defects Res Part A - Clin Mol Teratol 
103(8) : 680-691, 2015. doi : 10.1002/bdra.23385
5.  Morita KI, Naruto T, Tanimoto K, Yasukawa C, Oikawa 
Y, Masuda K, Imoto I, Inazawa J, Omura K, Harada 
H : Simultaneous detection of both single nucleotide vari-
ations and copy number alterations by next-generation se-
quencing in gorlin syndrome. PLoS One 10(11) : 1-12, 2015. 
doi : 10.1371/journal.pone.0140480
6.  Kohmoto T, Shono M, Naruto T, Watanabe M, Suga K, 
Nakagawa R, Kagami S, Masuda K, Imoto I : A novel 
frameshift mutation of CHD7 in a Japanese patient with 
CHARGE syndrome. Hum Genome Var 3(1) : 2015-2017, 
2016. doi : 10.1038/hgv.2016.4
7.  Watanabe M, Nakagawa R, Kohmoto T, Naruto T, Suga 
KI, Goji A, Horikawa H, Masuda K, Kagami S, Imoto 
I : Exome-first approach identified a novel gloss deletion as-
sociated with Lowe syndrome. Hum Genome Var 3(1) : 4-7, 
2016. doi : 10.1038/hgv.2016.37
8.  Watanabe M, Hayabuchi Y, Ono A, Naruto T, Horikawa 
H, Kohmoto T, Masuda K, Nakagawa R, Ito H, Kagami S, 
Imoto I : Detection of 1p36 deletion by clinical exome-first 
diagnostic approach. Hum Genome Var 3(1) : 5-8, 2016. 
doi : 10.1038/hgv.2016.6
9.  Mori T, Goji A, Toda Y, Ito H, Mori K, Kohmoto T, Imoto I, 
Kagami S : A 16q22.2-q23.1 deletion identified in a male in-
fant with West syndrome. Brain Dev 41(10) : 888-893, 2019. 
doi : 10.1016/j.braindev.2019.07.005
10.  Tokaji N, Ito H, Kohmoto T, Naruto T, Takahashi R, Goji 
A, Mori T, Toda Y, Saito M, Tange S, Masuda K, Kagami 
S, Imoto I : A rare male patient with classic Rett syndrome 
caused by MeCP2_e1 mutation. Am J Med Genet Part A 
176(3) : 699-702, 2018. doi : 10.1002/ajmg.a.38595
11.  van Ravenswaaij-Arts C, Martin DM : New insights and 
advances in CHARGE syndrome : Diagnosis, etiologies, 
treatments, and research discoveries. Am J Med Genet Part 
C Semin Med Genet 175(4) : 397-406, 2017. doi : 10.1002/
ajmg.c.31592
12.  Grozeva D, Carss K, Spasic-Boskovic O, Tejada MI, Gecz 
J, Shaw M, Corbett M, Haan E, Thompson E, Friend K, 
Hussain Z, Hackett A, Field  M, Renieri A, Stevenson R, 
Schwartz C, Floyd JA, Bentham J, Cosgrove C, Keavney 
B, Bhattacharya S : Targeted Next-Generation Sequencing 
Analysis of 1,000 Individuals with Intellectual Disability. 
Hum Mutat 12 : 1197-1204, 2015. doi : 10.1002/humu.22901
